University of California

University of Connecticut

Nof Corporation

Ohyun Kwon

Fuyuhiko Tamanoi

Hannah Fiji

Masaru Watanabe

Jau-Nian Chen

Kohei Yoshimura

Yi Chiao Fan

Jie Lu

Gabriel Fenteany

Johann Schredelseker

Kui Lu

Hirohito Shimizu

Jie Huang

Andrew Smaligo

Daniel Cruz

Agents, compositions, and methods for regulating cardiac rhythmicity are disclosed.

Anti-arrhythmicity agents

The present disclosure relates to methods of carbon-carbon bond fragmentation.

Methods of carbon-carbon bond fragmentation

The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same.

Small molecules for endothelial cell activation

The present invention relates, for example, to a liposome, which can be a basic liposome, a transferrin-conjugated liposome, or a pH-sensitive liposome, which encapsulates a compound that specifically inhibits the activity of a protein prenyltransferase, such as a RabGGTase and/or a GGTase I. The liposomes can be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.

Nanodrug targeting protein geranylgeranylation

This invention relates, e.g., to a compound, aplexone, and pharmaceutically acceptable salts and solvates, and functional variants, thereof. Methods of using the compounds and pharmaceutical compositions comprising them, e.g. to inhibit angiogenesis and to reduce cellular cholesterol levels, are also included.

Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis

The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of protein prenyltransferases including GGTase I and/or RabGGTase. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.

Inhibitors of protein prenyltransferases

A method for producing libraries of structurally and stereochemically diverse molecules that can be screened for biological or chemical activity. A library of 91 heterocyclic compounds composed of 16 distinct scaffolds was synthesized through a sequence of phosphine-catalyzed ring-forming reactions, Tebbe reactions, Diels-Alder reactions, and, in some cases, hydrolysis to illustrate the methods. Three compounds inhibiting migration of human breast cancer cells are identified from the library.

Compound libraries made through phosphine-catalyzed annulation/Tebbe/Diels-Alder reactions

The present invention is directed to novel compounds. These compounds can be useful in inhibiting the activity of GGTase I. The compounds can also be used as anti-cancer therapeutics including as part of methods for treating cancer, in assays, and in kits.

Growing community of inventors

Los Angeles, CA, United States of America

Ohyun Kwon